Estimation of Delirium Data Completeness

September 7, 2019 updated by: Efficacy Care R&D Ltd

Estimation of Delirium Data Completeness and Analysis of Underlying Systems Factors in a Retrospective Cohort

Currently physicians and nurses rely on their own clinical skills and experience to diagnose and record 'delirium' in the Electronic Health Records (EHR). This study aims to determine how delirium as a diagnosis is documented by clinicians in the EHR at Hadassah Hospital. The knowledge gained from this study will support the design of a better surveillance approach to monitoring delirium events in postoperative patients using electronic healthcare recorded data.

There is considerable uncertainty surrounding the quality of 'delirium' records in the Electronic Health Records (EHR). The reliability of this chart estimation has become questionable in the absence of an objective definition of 'delirium' and a lack of highly accurate diagnostic tools in the hospital setting.

Given the difficulty of accurately identifying delirium and the deficiency in the quality of EHR documentation, it is not surprising that delirium is grossly underestimated, undertreated, not properly recorded in the EHR or misreported. Data concordance plays a major role in documentation quality, especially for data-mining and knowledge extraction analysis, and therefore it is essential to address the reliability of 'delirium' labeled data within the EHR system.

Study Overview

Detailed Description

Clinical Background::

Postoperative encephalopathy known as "delirium" is a deleterious, potentially risky, and often preventable complication representing a serious "brain failure" condition, commonly seen in the intensive care unit (ICU) setting.

The etiology of postoperative delirium (POD) is likely to be a consequence of the physiological and biochemical derangement induced by the underlying surgical pathology, surgical trauma, pain, analgesia, and anesthesia. Common pathophysiological factors, processes, and conditions leading to delirium are multifactorial and could involve neurotransmitters, inflammatory processes, drugs, and oxygenation impairment. Multifactorial perioperative factors, such as anesthesia and adjuvant drugs, also play important roles in contributing to postoperative delirium. Perioperative care is, therefore, a potential focus for investigation of data-driven evidence to understand the POD prior to developing effective intervention tool.

Delirium Burden::

Delirium creates distinct emotional distress in patients, family and caregivers.

The burden of illness due to delirium is significant, with a higher incidence of postoperative complications, prolonged length of ICU and hospital stay, resulting in 30-day mortality and unplanned readmission when compared to patients without delirium. The long-term prospects of delirious patients show poor quality of life ('QoL') indicators related to functional decline, new institutionalization, persistent cognitive impairments and higher mortality, with persistent cognitive impairments in 12% of previously "cognitively well" patients, and an even higher percentage in elderly, obese, and previously admitted patients. The postoperative delirium is associated with longer-term cognitive decline and potentially 'portends descent to dementia' .

The mortality rate associated with delirium is approximately 40% , as high as acute myocardial infarction. The total cost estimates attributable to delirium ranged from $16,303 to $64,421 per patient, implying that the national burden of delirium on the health care system ranges from $38 billion to $152 billion each year in US. This cost is highly comparable to the substantial costs of falls and diabetes, which emphasizes the need to address this costly disorder with increased timeliness and urgency.

Standard of Care::

Efforts to detect delirium have relied upon two major methods , both of which fall short of the practical needs of a modern hospital environment. Screening instruments, largely based upon chart review, well-investigated risk factors and patient interview, have been unsuccessful due to the challenges of implementing these into clinical workflows and providing ongoing training for healthcare providers to use such instruments. In addition, they exhibit poor sensitivity in routine use. While the early detection of delirium provides clear and significant advantages in effective treatment, the screening tools available for the disorder are not efficient or effective enough to do so. Delirium is often underrecognized and misdiagnosed, exemplified in a 2014 study that found that the successful detection of the disorder by staff was only at 23%, even after extensive multimodal education about the disorder and how best to detect it.

Despite its importance for patient safety and public health, delirium is often unrecognized by clinicians, therefore the effective strategies of intervention remain elusive. Moreover, the presentation of delirium is heterogeneous and multifaceted, and measurement of delirium and its severity pose unique challenges.

Unmet Need::

The need exists for an objective, affordable and reliable modern assessment with the ability of early recognition, improved screening, and continuous monitoring of postoperative encephalopathy. The potential impact of such a tool has been recognized as highly important for the establishment of evidence-based data for better tracking prognosis, monitoring response to treatment and estimating the burden of care both during and after hospitalization. Nurses themselves recognize this unmet need. Many have argued that the current screening tests are too subjective and rely on each tester's interpretation.

Concept Creation::

The era of "Medical Big Data" and next-generation health analytics is well upon us. Conceptually, "Big Data" may include data-driven clinical features considered to be hidden, uncertain, unrecoverable and unmanageable for human interpretation without the help of computerized data processing and advance data-driven algorithms. As delirium in post-surgical patients is often hard to recognize and remains a largely untreated condition, it is hypothesized that an exploratory analysis of historical medical records by using an advanced algorithm could reveal novel and improved knowledge about the nature of delirium. However, the quality, computability, reliability, accuracy and completeness of the data are questionable.

Therefore this study aims to perform a retrospective exploratory analysis of historical records locked in one or more clinical databases (i.e. Metavision, EHR, AIMS, etc.), and/or in one or more hospital settings.

Study Type

Observational

Enrollment (Anticipated)

50000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • IL
      • Jerusalem, IL, Israel
        • Haddasah Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Sample Size: 50,000 Gender: M - 25,000; F - 25000 approx. Age: 18 and older General Health Status: All postoperative patients undergoing unplanned admission to an intensive care unit (ICU).

Total Number of Subjects Projected: It is expected that approximately 75,000 subjects will be enrolled (identified for further review) to produce 50,000 evaluable subjects.

Description

Inclusion Criteria:

  1. All postoperative patients aged 18 years and older; and
  2. Undergoing unplanned admission to an intensive care unit (ICU); or
  3. Major complications associated with either operating room procedure or anesthesia. Example: Cardiac or circulatory event and/or Cardiac arrest during or within 24 hours of operation or administration of anesthesia; or Acute myocardial infarction (AMI) during or within 48 hours of operation or administration of anesthesia; or
  4. Postoperative Central Nervous System (CNS) event (e.g., CVA, seizures, coma) during or within 48 hours of operation or administration of anesthesia; AND
  5. Respiratory failure not present prior to the 25th hour of hospitalization or not present before surgery;

Exclusion Criteria:

  1. Delirium present on admission; or
  2. any psychotic or degenerative related diagnosis on admission (e.g. Senile and presentile dementias such as Alzheimer's or Pick's dementia, Creutzfeldt-Jakob disease, Huntington's chorea, Wilson's disease).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Delirium
Time Frame: 12 months

The primary outcomes measured in this study are the number of cases determining the presence, absence, or likelihood of subsequent development of postoperative delirium.

(ICD-9-CM Codes Considered Evidence of Delirium: 290.3 Senile dementia with delirium; or 291 Alcohol-induced mental disorders; or 291.0 Alcohol withdrawal delirium; or 292 Drug-induced mental disorders; or 292.81 Drug-induced delirium; or 293 Transient mental disorders due to conditions classified elsewhere; or 293.1 Subacute delirium; or 780.09 Other alteration of consciousness )

12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of delirium
Time Frame: 30 days

CAM-S Score::

Delirium severity measure based on the Confusion Assessment Method (CAM-S). The severity score is created by an additive summary of the ratings ranging from 0-19 (long form). Higher scores indicate more severe delirium.

30 days
Severity of delirium
Time Frame: 30 days

DRS-R98 Score::

The Delirium Rating Scale (DRS) is a widely used delirium rating instrument that specifically, sensitively, and reliably measures delirium symptoms as rated by a psychiatrist or trained clinician.

Severity items are rated on a scale of 0-3 and diagnostic items are rated on a scale of 0-2 or 0-3. The maximum possible score for severity items is 39, while the maximum total score is 46. Higher scores indicate more severe delirium; score of 0 indicates no delirium.

30 days
ICU LOS
Time Frame: 30 days
days of Unplanned ICU hospitalization
30 days
In-patient mortality
Time Frame: 12 months
In-patient mortality
12 months
ICER
Time Frame: 12 months
The incremental cost-effectiveness ratio (ICER)
12 months
Readmission
Time Frame: 30 days
30-day readmission
30 days
in hospital mortality
Time Frame: 30 days
30-day hospital mortality
30 days
Direct Costs of Hospitalisation
Time Frame: 30 days
Total Hospitalization costs, including procedural complication costs, and/or any costs of pre-discharge treatment, drug, procedure-related complications and re-interventions;
30 days
LOS
Time Frame: 30 days
days of none-ICU hospitalization
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

October 1, 2019

Primary Completion (Anticipated)

November 1, 2020

Study Completion (Anticipated)

November 1, 2020

Study Registration Dates

First Submitted

September 5, 2019

First Submitted That Met QC Criteria

September 7, 2019

First Posted (Actual)

September 10, 2019

Study Record Updates

Last Update Posted (Actual)

September 10, 2019

Last Update Submitted That Met QC Criteria

September 7, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • Delirium-Retrospective Cohort

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Clinical Trials on none - observation only

3
Subscribe